Journal
ALLERGY
Volume 76, Issue 11, Pages 3349-3358Publisher
WILEY
DOI: 10.1111/all.14892
Keywords
biologicals; biomarkers; chronic rhinosinusitis; endotype; EPOS2020
Categories
Ask authors/readers for more resources
Endotyping is now favored over phenotype-based classifications in the management of Chronic Rhinosinusitis (CRS), particularly in challenging cases with nasal polyposis. The latest update from EPOS2020 includes revised classifications and care pathways for rhinosinusitis. Balancing the responsibility of managing patients' upper airway while protecting themselves from droplet and aerosol transmission is crucial for physicians and rhinologists during the COVID-19 pandemic.
Chronic rhinosinusitis (CRS) is a complex upper airway inflammatory disease with a broad spectrum of clinical variants. As our understanding of the disease pathophysiology evolves, so too does our philosophy towards the approach and management of CRS. Endotyping is gaining favour over phenotype-based classifications, owing to its potential in prognosticating disease severity and delivering precision treatment. Endotyping is especially useful in challenging CRS with nasal polyposis cases, for whom novel treatment options such as biologicals are now available. The latest European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS2020) reflects these changes with updated rhinosinusitis classifications and new integrated care pathways. With the coronavirus disease 2019 (COVID-19) pandemic, physicians and rhinologists have to balance the responsibility of managing their patients' upper airway while adequately protecting themselves from droplet and aerosol transmission. This review summarises the key updates from EPOS2020, endotype-based classification and biomarkers. The role of biologicals in CRS and the lessons we can draw from their use in severe asthma will be examined. Finally, the principles of CRS management during COVID-19 will also be discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available